BioSpace News Archive

Partner Therapeutics, Inc. (PTx) announced that Leukine® (sargramostim, rhu-GM-CSF) is being assessed in the SARPAC trial (sargramostim in patients with acute hypoxic respiratory failure due to COVID-19 – EudraCT #2020-001254-22) at University Hospital Ghent to treat patients with respiratory illness associated with COVID-19.

DYNALABS and Mayo Clinic have joined forces to launch ANiGENT, a new company whose proprietary software uses machine learning to deliver a state-of-the-art drug diversion surveillance system

Breaking research in AACC’s The Journal of Applied Laboratory Medicine shows that the fentanyl in epidurals can pass on to babies during labor.

Bright and early Monday morning, Hoth Therapeutics, Inc. released news that the Company had entered into a joint venture agreement with its joint venture partner, Voltron Therapeutics, Inc., for the “Joint Development for a Self-Assembling Vaccine for the Potential Prevention of the Coronavirus.”.

As lawmakers hurry to finalize a legislative package responding to the coronavirus pandemic, the U.S. Conference of Mayors is urging them to ensure a greater number of cities are eligible for federal resources.

SpendEdge, a leading provider of procurement market intelligence solutions, has announced the completion of their latest article on the keys to evaluate your inventory management process for biomedical devices.

Prevail Therapeutics Inc. announced that the U.S. Food and Drug Administration has granted Fast Track Designation for the Company’s experimental gene therapy program, PR006, to slow the progression of frontotemporal dementia with a GRN mutation.

Ampio Pharmaceuticals, Inc., a pre-revenue development stage biopharmaceutical company announced that it has suspended patient enrollment in its Phase 3 clinical trial of Ampion for the treatment of severe osteoarthritis of the knee.

Oncolytics Biotech® Inc. announced a favourable assessment from the Safety Committee following review of data from the window of opportunity study in early-stage breast cancer, known as AWARE-1.

Safe and effective in-office treatment clinically proven to reduce heavy menstrual bleeding, improve quality of life and preserve long-term uterine cavity access